Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FRANCIS MCGOWAN

Allopathic & Osteopathic Physicians Anesthesiology Pediatric Anesthesiology

NPI
1346200078
CMS profile
1227007
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$16.20

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $16.20 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Abbott Laboratories $16.20 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FRANCIS MCGOWAN

NPI 1346200078 · CMS profile ID 1227007

Allopathic & Osteopathic Physicians / Anesthesiology / Pediatric Anesthesiology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346200078?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FRANCIS MCGOWAN, NPI 1346200078, CMS profile ID 1227007. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346200078?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). FRANCIS MCGOWAN, NPI 1346200078, CMS profile ID 1227007. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346200078?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
FRANCIS MCGOWAN, NPI 1346200078, CMS profile ID 1227007, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1346200078?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $16.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $16.2002/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019372459 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $666.00 5
PY2023 $16.20 1
PY2024 $14.60 1
PY2025 $22.18 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $2,800.00 1
PY2022 Principal investigator $7,244.96 2
PY2021 Principal investigator $3,378.59 2
PY2020 Principal investigator $3,534.07 27
PY2019 Principal investigator $58,678.73 85

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

85 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $375.00 12/18/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691498485
Principal investigator 1 Merck Sharp & Dohme Corporation $0.23 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691521593
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691522579
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691522583
Principal investigator 1 Merck Sharp & Dohme Corporation $5.28 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691522585
Principal investigator 1 Merck Sharp & Dohme Corporation $0.26 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691523285
Principal investigator 1 Merck Sharp & Dohme Corporation $1.24 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691523289
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691523645
Principal investigator 1 Merck Sharp & Dohme Corporation $2.30 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691523647
Principal investigator 1 Merck Sharp & Dohme Corporation $23.28 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691523651
Principal investigator 1 Merck Sharp & Dohme Corporation $0.11 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691524449
Principal investigator 1 Merck Sharp & Dohme Corporation $0.12 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691524453
Principal investigator 1 Merck Sharp & Dohme Corporation $0.12 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691524457
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691540477
Principal investigator 1 Merck Sharp & Dohme Corporation $9.90 12/09/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691540819
Principal investigator 1 Merck Sharp & Dohme Corporation $25.00 11/22/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691498483
Principal investigator 1 Merck Sharp & Dohme Corporation $11,284.80 11/18/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691498479
Principal investigator 1 Merck Sharp & Dohme Corporation $391.14 11/12/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691518803
Principal investigator 1 Merck Sharp & Dohme Corporation $134.68 11/12/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691537343
Principal investigator 1 Merck Sharp & Dohme Corporation $1.82 11/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691522587
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 11/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691522925
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 11/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691524749
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 11/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691525367
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 11/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691525675
Principal investigator 1 Merck Sharp & Dohme Corporation $3.68 11/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691525679
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 11/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691525683
Principal investigator 1 Merck Sharp & Dohme Corporation $521.52 11/05/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691537345
Principal investigator 1 Merck Sharp & Dohme Corporation $1,625.00 10/25/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691504615
Principal investigator 1 Merck Sharp & Dohme Corporation $9,159.80 10/25/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691504957
Principal investigator 1 Merck Sharp & Dohme Corporation $1.26 10/03/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404139
Principal investigator 1 Merck Sharp & Dohme Corporation $1.26 10/03/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691507629
Principal investigator 1 Merck Sharp & Dohme Corporation $494.68 09/12/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691422287
Principal investigator 1 Merck Sharp & Dohme Corporation $1,500.00 08/26/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691421177
Principal investigator 1 Merck Sharp & Dohme Corporation $97.05 08/23/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691366121
Principal investigator 1 Merck Sharp & Dohme Corporation $234.31 08/14/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691366182
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 08/14/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691537747
Principal investigator 1 Merck Sharp & Dohme Corporation $118.80 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691420705
Principal investigator 1 Merck Sharp & Dohme Corporation $2.08 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691420723
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691420787
Principal investigator 1 Merck Sharp & Dohme Corporation $6.84 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691421097
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691422938
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691423323
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691423325
Principal investigator 1 Merck Sharp & Dohme Corporation $12.24 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691423329
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691423335
Principal investigator 1 Merck Sharp & Dohme Corporation $3.08 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691423337
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691423437
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691423441
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691423443
Principal investigator 1 Merck Sharp & Dohme Corporation $4.14 08/08/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691423447
Principal investigator 1 Merck Sharp & Dohme Corporation $6.99 08/01/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691366117
Principal investigator 1 Merck Sharp & Dohme Corporation $0.12 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691376111
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691376773
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691377885
Principal investigator 1 Merck Sharp & Dohme Corporation $3.40 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691403183
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691403185
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691403195
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691403643
Principal investigator 1 Merck Sharp & Dohme Corporation $4.14 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691403645
Principal investigator 1 Merck Sharp & Dohme Corporation $5.28 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404123
Principal investigator 1 Merck Sharp & Dohme Corporation $9.90 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404127
Principal investigator 1 Merck Sharp & Dohme Corporation $0.11 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404281
Principal investigator 1 Merck Sharp & Dohme Corporation $0.12 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404283
Principal investigator 1 Merck Sharp & Dohme Corporation $0.23 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404287
Principal investigator 1 Merck Sharp & Dohme Corporation $0.26 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404373
Principal investigator 1 Merck Sharp & Dohme Corporation $1.24 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404377
Principal investigator 1 Merck Sharp & Dohme Corporation $1.90 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404379
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404383
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404457
Principal investigator 1 Merck Sharp & Dohme Corporation $23.28 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691404459
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 07/10/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691515201
Principal investigator 1 Merck Sharp & Dohme Corporation $144.60 06/20/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691343821
Principal investigator 1 Merck Sharp & Dohme Corporation $227.32 06/19/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691342535
Principal investigator 1 Merck Sharp & Dohme Corporation $10,100.00 05/20/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691322047
Principal investigator 1 Merck Sharp & Dohme Corporation $1,500.00 05/20/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691326736
Principal investigator 1 Merck Sharp & Dohme Corporation $391.14 04/30/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691422281
Principal investigator 1 Merck Sharp & Dohme Corporation $494.68 04/30/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691422283
Principal investigator 1 Merck Sharp & Dohme Corporation $758.88 04/30/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691422289
Principal investigator 1 Merck Sharp & Dohme Corporation $35.85 04/16/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691342997
Principal investigator 1 Merck Sharp & Dohme Corporation $8,700.00 03/15/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691322553
Principal investigator 1 Merck Sharp & Dohme Corporation $9,300.00 03/15/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691326747
Principal investigator 1 Merck Sharp & Dohme Corporation $13.50 03/07/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691343819
Principal investigator 1 Merck Sharp & Dohme Corporation $213.00 02/11/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691342461
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 02/11/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691343825
Principal investigator 1 Merck Sharp & Dohme Corporation $19.59 02/11/2019 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691343827